Noticias Recursion Pharmaceuticals Inc - RXRX | Acciones NASDAQ | ADVFN

US Dollar vs MXN

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (RXRX) Noticias

Recursion Pharmaceuticals Inc (RXRX)

7.24

-0.45

(-5.85%)

Cerrado 02 Febrero 3:00PM

Delayed by 15 minutes

7.2499

0.0099

(0.14%)

Fuera de horario: 6:59PM

Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Recursion and Exscientia Shareholders Approve the Proposed Combination

Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have each received...

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

SALT LAKE CITY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

2
3
4
Próximo

bwrbad

bwrbad 2 días hace

YouTube influencer position - write or call cGibson@recursion.com

TucsonPhil

TucsonPhil 4 días hace

Exactly, when we see the lending fees start to rise, then I will buy more. Brokers always make money, even when investors lose.

bwrbad

bwrbad 4 días hace

they all do etard fidal TDA, but that gives the opportunity to buy low. This RxRx defines the future of MED world in AI stage- just buying little little within affordability. definitively it will grow like MSTF GOOG AAPL NVDA AMZN.., All drug lords pfizer, j&j eli, merck roche AZ BMS are lining up behind, just give few months to a year for first $100

TucsonPhil

TucsonPhil 5 días hace

Fidelity is loaning shares to shorts.

bwrbad

bwrbad 5 días hace

next piece of clinical update will take it above 20 and after that it is in different league.

bwrbad

bwrbad 1 semana hace

Sure looks like early days of ISRG ILMN,

TucsonPhil

TucsonPhil 1 semana hace

Nvidia invested $50M in this company. ARK is a holder. This will be huge, once their first find gets FDA approval, and proof of concept is secured.

bwrbad

bwrbad 1 semana hace

interesting no posters in this
future $200 - $300 stock, and that future not far - see the quality of clinical data, target diseases, and the time it took to reach there - not standard 20 ys but 3y to ph3 and a large advancing failure resistant AI powered pipeline

bwrbad

bwrbad 1 semana hace

change of heart -going up.

bwrbad

bwrbad 1 semana hace

bwrbad

bwrbad 2 semanas hace

promised to accumulate 10k shares before Q end and hold for years. predict this issue never go BK, do RS, and one day go beyond 200+ like established big cap security issues.

bwrbad

bwrbad 2 semanas hace

bwrbad

bwrbad 3 semanas hace

believe in miracle ----- come to RXRX------

TucsonPhil

TucsonPhil 3 semanas hace

Looks like Lilly is late to the party.

https://www.statnews.com/2025/01/10/eli-lilly-andreessen-horowitz-500-million-venture-fund-ai-focus/

bwrbad

bwrbad 4 semanas hace

cursion-re-cursion in flame after FDA REC 3565 blessings

bwrbad

bwrbad 4 semanas hace

Gibson🤢🥵🥶😷Gibson

bwrbad

bwrbad 1 mes hace

bwrbad

bwrbad 1 mes hace

balding haircut at RXRX

Monksdream

Monksdream 1 mes hace

bwrbad

bwrbad 1 mes hace

out for now, let CEO work his magic if he has one under his sleeve

bwrbad

bwrbad 1 mes hace

is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.

bwrbad

bwrbad 2 meses hace

bwrbad

bwrbad 2 meses hace

RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......

bwrbad

bwrbad 2 meses hace

RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.

bwrbad

bwrbad 2 meses hace

market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.

TucsonPhil

TucsonPhil 2 meses hace

RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.

bwrbad

bwrbad 2 meses hace

Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%

JJ8

JJ8 2 meses hace

Rxrx share price Long Tail Up since 06 Dec 2024.

paperman

paperman 2 meses hace

Phase 1 news expected tonight at conference.

paperman

paperman 2 meses hace

Phase 1 news expected tonight at conference.

bwrbad

bwrbad 2 meses hace

this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...

JJ8

JJ8 2 meses hace

Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!

TucsonPhil

TucsonPhil 2 meses hace

Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.

bwrbad

bwrbad 2 meses hace

RxRx going to be top player in future pharma drug discovery

TucsonPhil

TucsonPhil 2 meses hace

Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.

bwrbad

bwrbad 2 meses hace

GOOG -- RxRx -- NVDA -- RxRx -- MSFT

bwrbad

bwrbad 2 meses hace

agree but better, much bigger scope, on way to become a high flying company of the future
price target 150 in two year

uksausage

uksausage 2 meses hace

no it is the PLTR of Drug discovery
both rely on NVDA to run fast

bwrbad

bwrbad 2 meses hace

started buying little little- this is NVDA of DRUG DISCOVERY

ToucanYoucan

ToucanYoucan 2 meses hace

$RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.

bwrbad

bwrbad 2 meses hace

high potential if delivers,

TucsonPhil

TucsonPhil 2 meses hace

Good gains in past week, but looks like it is getting ready to drift lower again.

TucsonPhil

TucsonPhil 2 meses hace

First patient dosed.

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study

lambchops

lambchops 2 meses hace

Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

LC

RXRX

ToucanYoucan

ToucanYoucan 2 meses hace

$RXRX - Having a huge day here!!

ToucanYoucan

ToucanYoucan 2 meses hace

$RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo

TucsonPhil

TucsonPhil 3 meses hace

Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.

Monksdream

Monksdream 3 meses hace

Monksdream

Monksdream 3 meses hace

Monksdream

Monksdream 3 meses hace

Recursion Pharmaceuticals

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones